Skip to main content
. 2022 Sep 21;54(9):1563–1576. doi: 10.1038/s12276-022-00853-6

Fig. 3. PLD1 inhibition suppresses CRC cell proliferation but promotes apoptosis and is safe in vitro with no toxicity.

Fig. 3

a Cell viability was examined in DLD1 cells treated with PLD inhibitors in a time-dependent (for 48 h) and dose-dependent (at 2 μM) manner. b A3373 (2 μM) and 5-FU (10 μM) treatment was administered to the indicated cells, and the cell cycle was analyzed. The population at the indicated cell cycle phase was quantitated. c CRC cells were treated with the indicated drugs for 48 h, and apoptosis was analyzed in the presence of 1% FBS using annexin V and flow cytometry. d, e hERG ligand-binding assay (d) and patch-clamp assay (e) in HEK293 cells transfected with hERG. f Plasma concentration-time curves of A3373. Single-dose plasma pharmacokinetics of A3373 in male ICR mice following 5 mg/kg (intravenous injection, IV) or 10 mg/kg (peroral injection, PO). Data are presented as the mean (n = 3). The results are representative of at least three independent experiments and presented as the mean ± SD. **P < 0.01; ***P < 0.001.